DK0806948T3 - Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin - Google Patents
Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutyninInfo
- Publication number
- DK0806948T3 DK0806948T3 DK96906202T DK96906202T DK0806948T3 DK 0806948 T3 DK0806948 T3 DK 0806948T3 DK 96906202 T DK96906202 T DK 96906202T DK 96906202 T DK96906202 T DK 96906202T DK 0806948 T3 DK0806948 T3 DK 0806948T3
- Authority
- DK
- Denmark
- Prior art keywords
- desethyloxybutynin
- oxybutynin
- urinary incontinence
- treatment
- disclosed
- Prior art date
Links
- SNIBJKHIKIIGPR-HXUWFJFHSA-N 4-(ethylamino)but-2-ynyl (2s)-2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@@](O)(C(=O)OCC#CCNCC)C=2C=CC=CC=2)CCCCC1 SNIBJKHIKIIGPR-HXUWFJFHSA-N 0.000 title abstract 3
- 206010046543 Urinary incontinence Diseases 0.000 title abstract 2
- SWIJYDAEGSIQPZ-VZYDHVRKSA-N esoxybutynin chloride Chemical compound Cl.C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 SWIJYDAEGSIQPZ-VZYDHVRKSA-N 0.000 title 1
- XIQVNETUBQGFHX-JOCHJYFZSA-N esoxybutynin Chemical compound C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-JOCHJYFZSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 1
- SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960005434 oxybutynin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/381,542 US5532278A (en) | 1995-01-31 | 1995-01-31 | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
| US08/480,194 US5677346A (en) | 1995-01-31 | 1995-06-07 | Treating urinary incontinence using (S)-desethyloxybutynin |
| PCT/US1996/001053 WO1996023492A1 (en) | 1995-01-31 | 1996-01-25 | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0806948T3 true DK0806948T3 (da) | 2000-12-18 |
Family
ID=27009434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96906202T DK0806948T3 (da) | 1995-01-31 | 1996-01-25 | Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5677346A (cs) |
| EP (1) | EP0806948B1 (cs) |
| JP (1) | JPH11511730A (cs) |
| KR (1) | KR100390271B1 (cs) |
| CN (1) | CN1151786C (cs) |
| AT (1) | ATE196252T1 (cs) |
| AU (1) | AU706741B2 (cs) |
| BR (1) | BR9607001A (cs) |
| CA (1) | CA2211400C (cs) |
| CZ (1) | CZ290093B6 (cs) |
| DE (1) | DE69610290T2 (cs) |
| DK (1) | DK0806948T3 (cs) |
| ES (1) | ES2150663T3 (cs) |
| FI (1) | FI973163L (cs) |
| GR (1) | GR3034974T3 (cs) |
| HU (1) | HUP9800794A3 (cs) |
| NO (1) | NO315927B1 (cs) |
| NZ (1) | NZ303372A (cs) |
| PL (1) | PL182768B1 (cs) |
| PT (1) | PT806948E (cs) |
| RU (1) | RU2181589C2 (cs) |
| SK (1) | SK283313B6 (cs) |
| UA (1) | UA45387C2 (cs) |
| WO (1) | WO1996023492A1 (cs) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736577A (en) * | 1995-01-31 | 1998-04-07 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
| US6171298B1 (en) | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
| WO1998011888A1 (en) * | 1996-09-19 | 1998-03-26 | American Home Products Corporation | Method of treating urinary incontinence |
| US6123961A (en) * | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| EP1041981A2 (en) * | 1997-12-31 | 2000-10-11 | Sepracor, Inc. | $i(S)-PROCYCLIDINE FOR TREATING URINARY INCONTINENCE |
| US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
| US6013830A (en) * | 1998-03-30 | 2000-01-11 | Sepracor Inc. | Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols |
| ME00850B (me) * | 1998-08-27 | 2008-08-07 | Pfizer Health Ab | Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži |
| WO2000071108A2 (en) | 1999-05-20 | 2000-11-30 | Sepracor Inc. | Methods for treatment of asthma using s-oxybutynin |
| US6432446B2 (en) * | 2000-02-03 | 2002-08-13 | Bridge Pharma, Inc. | Non-arrhythmogenic metabolite of oxybutynin |
| US6521724B2 (en) | 2000-03-10 | 2003-02-18 | E. I. Du Pont De Nemours And Company | Polymerization process |
| US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| BR0110381A (pt) | 2000-04-26 | 2003-12-30 | Watson Pharmaceuticals Inc | Minimizando experiência adversa associada com terapia com oxibutinina |
| US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| AU2000255966B2 (en) * | 2000-06-07 | 2005-03-24 | Allergan Sales, Llc | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
| ES2283425T3 (es) * | 2000-08-03 | 2007-11-01 | Antares Pharma Ipl Ag | Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados. |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| WO2005039531A1 (en) | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| DE10103262A1 (de) * | 2001-01-25 | 2002-08-01 | Axel Schmidt-Dossi | Arzneimittel gegen Blasenfunktionsstörung |
| DE60234318D1 (de) * | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| CN1536986B (zh) * | 2001-03-27 | 2012-07-04 | 沃纳奇尔科特(爱尔兰)有限公司 | 用于抗微生物剂给药的阴道内药物递送装置 |
| US20030027856A1 (en) * | 2001-06-29 | 2003-02-06 | Aberg A.K. Gunnar | Tolterodine metabolites |
| BR0206300A (pt) * | 2001-11-05 | 2008-04-08 | Upjohn Co | composição farmacêutica para tratar distúrbio urinário em um mamìfero e uso |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
| JP2005516992A (ja) * | 2001-12-21 | 2005-06-09 | ブリッジ ファーマ、インコーポレイテッド | オキシブチニンの非心律動異常惹起性代謝物 |
| DK1426049T3 (da) * | 2002-12-02 | 2005-08-22 | Sanol Arznei Schwarz Gmbh | Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom |
| RU2241442C1 (ru) * | 2003-09-17 | 2004-12-10 | Научный центр акушерства, гинекологии и перинатологии РАМН | Вагинальные суппозитории для лечения императивного недержания мочеиспускания |
| US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| BRPI0812000A2 (pt) * | 2007-05-30 | 2014-11-18 | Microdose Therapeutx Inc | Métodos e composições para administração de oxibutinina |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| PH12013500221A1 (en) | 2010-08-03 | 2017-08-23 | Altherx Inc | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| AR089957A1 (es) | 2012-02-09 | 2014-10-01 | Altherx Inc | Combinaciones farmaceuticas, combinaciones sinergicas |
| JP2012176958A (ja) * | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| US20160151321A1 (en) | 2012-11-13 | 2016-06-02 | Dinesh C. Patel | Methods for the treatment of sialorrhea |
| US20140135392A1 (en) * | 2012-11-13 | 2014-05-15 | NeuRx Pharmaceuticals LLC | Methods for the treatment of sialorrhea |
| CN104116760A (zh) * | 2014-07-14 | 2014-10-29 | 玉庆花 | 一种治疗遗尿的口服液 |
| CN107205964A (zh) | 2014-12-03 | 2017-09-26 | 威力塞帕特治疗股份有限公司 | 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 |
| EP3365321B1 (en) | 2015-10-23 | 2023-12-13 | B3AR Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL267508A (cs) * | 1960-07-26 | |||
| BE902605A (fr) * | 1985-06-06 | 1985-09-30 | Therabel Res S A N V | Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition. |
| MX9202350A (es) * | 1991-05-20 | 1992-11-01 | Alza Corp | Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol. |
| JP3066515B2 (ja) * | 1992-11-11 | 2000-07-17 | 久光製薬株式会社 | 尿失禁治療用経皮投与製剤 |
| US5750137A (en) * | 1993-09-29 | 1998-05-12 | Taskovich; Lina Tormen | Monoglyceride/lactate ester permeation enhancer |
-
1995
- 1995-06-07 US US08/480,194 patent/US5677346A/en not_active Expired - Fee Related
-
1996
- 1996-01-25 SK SK1035-97A patent/SK283313B6/sk unknown
- 1996-01-25 BR BR9607001A patent/BR9607001A/pt not_active IP Right Cessation
- 1996-01-25 UA UA97084420A patent/UA45387C2/uk unknown
- 1996-01-25 FI FI973163A patent/FI973163L/fi not_active IP Right Cessation
- 1996-01-25 WO PCT/US1996/001053 patent/WO1996023492A1/en not_active Ceased
- 1996-01-25 NZ NZ303372A patent/NZ303372A/xx unknown
- 1996-01-25 HU HU9800794A patent/HUP9800794A3/hu unknown
- 1996-01-25 RU RU97114572/14A patent/RU2181589C2/ru not_active IP Right Cessation
- 1996-01-25 ES ES96906202T patent/ES2150663T3/es not_active Expired - Lifetime
- 1996-01-25 CA CA002211400A patent/CA2211400C/en not_active Expired - Fee Related
- 1996-01-25 PT PT96906202T patent/PT806948E/pt unknown
- 1996-01-25 PL PL96321498A patent/PL182768B1/pl not_active IP Right Cessation
- 1996-01-25 CZ CZ19972421A patent/CZ290093B6/cs not_active IP Right Cessation
- 1996-01-25 AU AU49664/96A patent/AU706741B2/en not_active Ceased
- 1996-01-25 KR KR1019970705184A patent/KR100390271B1/ko not_active Expired - Fee Related
- 1996-01-25 AT AT96906202T patent/ATE196252T1/de not_active IP Right Cessation
- 1996-01-25 CN CNB961928891A patent/CN1151786C/zh not_active Expired - Fee Related
- 1996-01-25 DK DK96906202T patent/DK0806948T3/da active
- 1996-01-25 JP JP8523636A patent/JPH11511730A/ja not_active Ceased
- 1996-01-25 EP EP96906202A patent/EP0806948B1/en not_active Expired - Lifetime
- 1996-01-25 DE DE69610290T patent/DE69610290T2/de not_active Expired - Fee Related
-
1997
- 1997-07-30 NO NO19973516A patent/NO315927B1/no unknown
-
2000
- 2000-11-24 GR GR20000402596T patent/GR3034974T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0806948T3 (da) | Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin | |
| CA2257121A1 (en) | Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin | |
| NO20002172L (no) | FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin | |
| DK0814796T3 (da) | Anvendelse af et R-NSAID i en protektiv sammensætning til behandling af kolorektal cancer | |
| NO179250C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol | |
| DK0867179T3 (da) | Sammensætning af L-DOPA-estere | |
| AU7578894A (en) | Methods for inhibiting smooth muscle cell proliferation and restinosis | |
| DK0869808T3 (da) | Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation | |
| MY129473A (en) | 3,3-diarylpropylamines, their use and preparation | |
| BR9813767A (pt) | Processo e composição para tratar glaucoma de glc1a | |
| MY119375A (en) | Treatment of tinnitus using neuroprotective agents | |
| NO20000093L (no) | (+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser | |
| DE69328838D1 (de) | Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten | |
| DE69808440D1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
| HU9303000D0 (en) | Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof | |
| NO984920D0 (no) | Sammensetninger omfattende en nitroneforbindelse for anvendelse ved behandling av okulµr inflammasjon | |
| TR199801184T2 (xx) | Analjezik tesirli yeni bile�ikler. | |
| GEP20012511B (en) | Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis | |
| WO2001000187A3 (en) | Pharmaceutical composition containing sibutramine and a lipase inhibitor | |
| WO1999033454A3 (en) | S-procyclidine for treating urinary incontinence | |
| WO2000076490A3 (en) | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin | |
| WO1996021670A3 (en) | Antifungal fusacandins | |
| WO1999033453A3 (en) | R-procyclidine for treating urinary incontinence | |
| JO1738B1 (en) | A new therapeutically active compound | |
| MY110416A (en) | Composition for the treatment of schizophrenia. |